Medical device business Baymatob will use the funding to finalise development of ‘Oli’, its world first AI-powered maternal-foetal health platform that saves lives by providing early warning for serious, treatable complications in pregnancy and labour, such as postpartum haemorrhage, stillbirth, and uterine rupture.

Postpartum haemorrhage (PPH) is one of the leading causes of maternal mortality in Australia and the leading cause of preventable maternal death worldwide.

Trials are underway at Royal North Shore Hospital and The Royal Hospital for Women, and in the United States for the Oli-PPH Early Warning System.

The Medical Devices Fund enables the entrepreneurs to accelerate development and use of their devices to improve patient care within the NSW Health system.

Recipients will use the funding for product development, scaleup, testing, IP protections, regulatory submissions, commercial readiness and clinical trials.

The other three Medical Device Fund recipients are:

Amazing Gut has designed a wireless home-use biofeedback device used to facilitate exercises for improved control of bowel function in patients.

Kraken Coding has developed a platform that directly influences clinical decision-making related to treatment and prioritisation. Clinical Branches replaces static medical guidelines with interactive, patient-specific decision pathways. It asks clinicians a series of structured clinical questions and, based on their answers, instantly generates a concise, tailored summary of what to do, at the bedside, when it's needed.

Roam Technologies has created an ultra-portable oxygen concentrator for patients with chronic respiratory diseases. Weighing under 2 kg and adapting to each user’s breathing pattern, JUNO replaces bulky stationary units such as large oxygen tanks and clinically inadequate portable devices, enabling mobility, independence, and cost-effective care. The device bridges the gap between clinical oxygen therapy and the necessities of real-world use.